Clinical Trial Update: Her-2/Neu in Patients With Metastatic Breast Cancer (AdHERe) [Phase 1]

View source ↗

Summary

Phase 1 trial update on HER-2/neu targeting in patients with metastatic breast cancer (AdHERe), sponsored by the Ontario Clinical Oncology Group; the study stat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: Ontario Clinical Oncology Group (OCOG) | Conditions: Metastatic Breast Cancer | Phase 1 | Status: COMPLETED